Completed PHASE4 INTERVENTIONAL 2-arm NCT00207363

Does Induction PEG-Intron in Combination With Rebetol Enhance the Sustained Response Rates in Patients With CHC

Does Induction PEG-Intron in Combination With Rebetol Enhance the Sustained Response Rates in Patients With Chronic Hepatitis C

Sponsor: Brooke Army Medical Center

Conditions Hepatitis C

Interventions Ribavirin, Peg interferon alfa 2b induction therapy

Updated 7 times since 2017 Last updated: Feb 13, 2012 Started: Feb 28, 2002 Primary completion: Jan 31, 2010 Completion: Jan 31, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE4 trial investigates Hepatitis C and is currently completed. Brooke Army Medical Center leads this study, which shows 7 recorded versions since 2002 — indicating limited longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE4
Sep 2024 — Sep 2025 [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
Jun 2018 — Jan 2021 [monthly]

Completed PHASE4

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE4
Jan 2017 — Feb 2017 [monthly]

Completed PHASE4

First recorded

Feb 2002

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Brooke Army Medical Center
T.R.U.E. Research Foundation

Data source: Brooke Army Medical Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Fort Sam Houston, United States